Alcon Inc (ALC)
78.48
-0.52
(-0.66%)
USD |
NYSE |
Apr 18, 16:00
78.48
0.00 (0.00%)
After-Hours: 19:42
Alcon Cash from Investing (TTM)
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | -1.865B |
| September 30, 2022 | -1.364B |
| June 30, 2022 | -1.317B |
| March 31, 2022 | -1.67B |
| December 31, 2021 | -1.198B |
| September 30, 2021 | -1.085B |
| June 30, 2021 | -1.014B |
| Date | Value |
|---|---|
| March 31, 2021 | -599.00M |
| December 31, 2020 | -572.00M |
| September 30, 2020 | -624.00M |
| June 30, 2020 | -654.00M |
| March 31, 2020 | -693.00M |
| December 31, 2019 | -1.011B |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-1.865B
Minimum
Dec 2022
-572.00M
Maximum
Dec 2020
-1.051B
Average
-1.014B
Median
Jun 2021
Cash from Investing (TTM) Benchmarks
| AC Immune SA | 73.11M |
| CRISPR Therapeutics AG | 374.65M |
| Addex Therapeutics Ltd | -0.0064M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 49.71M |